Predictors of opioid misuse in patients with chronic pain: a prospective cohort study

Timothy J Ives, Paul R Chelminski, Catherine A Hammett-Stabler, Robert M Malone, J Stephen Perhac, Nicholas M Potisek, Betsy Bryant Shilliday, Darren A DeWalt, Michael P Pignone, Timothy J Ives, Paul R Chelminski, Catherine A Hammett-Stabler, Robert M Malone, J Stephen Perhac, Nicholas M Potisek, Betsy Bryant Shilliday, Darren A DeWalt, Michael P Pignone

Abstract

Background: Opioid misuse can complicate chronic pain management, and the non-medical use of opioids is a growing public health problem. The incidence and risk factors for opioid misuse in patients with chronic pain, however, have not been well characterized. We conducted a prospective cohort study to determine the one-year incidence and predictors of opioid misuse among patients enrolled in a chronic pain disease management program within an academic internal medicine practice.

Methods: One-hundred and ninety-six opioid-treated patients with chronic, non-cancer pain of at least three months duration were monitored for opioid misuse at pre-defined intervals. Opioid misuse was defined as: 1. Negative urine toxicological screen (UTS) for prescribed opioids; 2. UTS positive for opioids or controlled substances not prescribed by our practice; 3. Evidence of procurement of opioids from multiple providers; 4. Diversion of opioids; 5. Prescription forgery; or 6. Stimulants (cocaine or amphetamines) on UTS.

Results: The mean patient age was 52 years, 55% were male, and 75% were white. Sixty-two of 196 (32%) patients committed opioid misuse. Detection of cocaine or amphetamines on UTS was the most common form of misuse (40.3% of misusers). In bivariate analysis, misusers were more likely than non-misusers to be younger (48 years vs 54 years, p < 0.001), male (59.6% vs. 38%; p = 0.023), have past alcohol abuse (44% vs 23%; p = 0.004), past cocaine abuse (68% vs 21%; p < 0.001), or have a previous drug or DUI conviction (40% vs 11%; p < 0.001%). In multivariate analyses, age, past cocaine abuse (OR, 4.3), drug or DUI conviction (OR, 2.6), and a past alcohol abuse (OR, 2.6) persisted as predictors of misuse. Race, income, education, depression score, disability score, pain score, and literacy were not associated with misuse. No relationship between pain scores and misuse emerged.

Conclusion: Opioid misuse occurred frequently in chronic pain patients in a pain management program within an academic primary care practice. Patients with a history of alcohol or cocaine abuse and alcohol or drug related convictions should be carefully evaluated and followed for signs of misuse if opioids are prescribed. Structured monitoring for opioid misuse can potentially ensure the appropriate use of opioids in chronic pain management and mitigate adverse public health effects of diversion.

References

    1. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioid analgesics. JAMA. 2000;283:1710–14. doi: 10.1001/jama.283.13.1710.
    1. Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manage. 1996;11:203–17. doi: 10.1016/0885-3924(95)00187-5.
    1. Portenoy RK. Chronic opioid therapy in nonmalignant pain. J Pain Symptom Manag. 1990;5:S46–62.
    1. Turk DC, Okifuji A. Assessment of patients' reporting of pain: an integrated perspective. Lancet. 1999;353:1784–1788. doi: 10.1016/S0140-6736(99)01309-4.
    1. Burton AK, Tillotson KM, Main CJ, Hollis S. Psychosocial predictors of outcome in acute and subchronic low back trouble. Spine. 1995;20:722–728.
    1. Melzack R. The tragedy of needless pain. Sci Am. 1990;262:27–33.
    1. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997–2002. J Pain Symptom Manage. 2004;28:176–188. doi: 10.1016/j.jpainsymman.2004.01.003.
    1. Nonmedical use of prescription-type drugs among youths and young adults . National Household Survey on Drug Abuse. SAMHSA, U.S. Department of Health and Human Services; 2001.
    1. OxyContin®: Diversion & Abuse. US Drug Enforcement Agency, Office of Diversion Control. 2003.
    1. Ballesteros MF, Budnitz DS, Sanford CP, Gilchrist J, Agyekum GA, Butts J. Increase in deaths due to methadone in North Carolina. JAMA. 2003;290:40. doi: 10.1001/jama.290.1.40.
    1. Caravati EM, Nangel B, Rolfs RT, Peterson-Porucznik CA. Increase in poisoning deaths caused by non-illicit drugs – Utah, 1991–2003. MMWR. 2005;54:33–36.
    1. Soderstrom CA, Dischinger PC, Kerns TJ, Kufera JA, Mitchell KA, Scalea TM. Epidemic increases in cocaine and opiate use by trauma center patients: documentation with a large clinical toxicology database. J Trauma. 2001;51:557–564.
    1. Joranson DE, Carrow GM, Ryan KM, Schaefer L, Gilson AM, Good P, Eadie J, Peine S, Dahl JL. Pain management and prescription monitoring. J Pain Symptom Manage. 2002;23:231–238. doi: 10.1016/S0885-3924(01)00410-9.
    1. Fishman SM, Papazian JS, Gonzalez S, Riches PS, Gilson A. Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain. Pain Med. 2004;5:309–324. doi: 10.1111/j.1526-4637.2004.04049.x.
    1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–657. doi: 10.1046/j.1526-4610.2001.041007646.x.
    1. Ghodse H. Pain, anxiety and insomnia – a global perspective on the relief of suffering: comparative review. Br J Psychiatry. 2003;183:15–21. doi: 10.1192/bjp.183.1.15.
    1. Gardner-Nix J. Principles of opioid use in chronic noncancer pain. CMAJ. 2003;169:38–43.
    1. Jamison RN, Raymond SA, Slawsby EA, Nedeljkovic SS, Katz NP. Opioid therapy for chronic noncancer back pain. A randomized prospective study. Spine. 1998;23:2591–2600. doi: 10.1097/00007632-199812010-00014.
    1. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348:1223–1232. doi: 10.1056/NEJMoa021420.
    1. Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, Kalso E. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ. 2001;322:1154–1158. doi: 10.1136/bmj.322.7295.1154.
    1. Ytterberg SR, Mahowald ML, Woods SR. Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis Rheum. 1998;41:1603–1612. doi: 10.1002/1529-0131(199809)41:9<1603::AID-ART10>;2-U.
    1. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003;60:927–934.
    1. Friedman R, Li V, Mehrotra D. Treating pain patients at risk: evaluation of a screening tool in opioid-treated pain patients with and without addiction. Pain Med. 2003;4:182–185. doi: 10.1046/j.1526-4637.2003.03017.x.
    1. Passik SD, Kirsh KL. The need to identify predictors of aberrant drug-related behavior and addiction in patients being treated with opioids for pain. Pain Med. 2003;4:186–189. doi: 10.1046/j.1526-4637.2003.03018.x.
    1. Dunbar SA, Katz NP. Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of 20 cases. J Pain Symptom Manage. 1996;11:163–171. doi: 10.1016/0885-3924(95)00165-4.
    1. Rosenblum A, Joseph H, Fong C, Kipnis S, Cleeland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. JAMA. 2003;289:2370–2378. doi: 10.1001/jama.289.18.2370.
    1. Miller NS, Greenfeld A. Patient characteristics and risks factors for development of dependence on hydrocodone and oxycodone. Am J Ther. 2004;11:26–32. doi: 10.1097/00045391-200401000-00008.
    1. Adams NJ, Plane MB, Fleming MF, Mundt MP, Saunders LA, Stauffacher EA. Opioids and the treatment of chronic pain in a primary care sample. J Pain Symptom Manage. 2001;22:791–796. doi: 10.1016/S0885-3924(01)00320-7.
    1. Katz NP, Sherburne S, Beach M, Rose RJ, Vielguth J, Bradley J, Fanciullo GJ. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg. 2003;97:1097–1102. doi: 10.1213/01.ANE.0000080159.83342.B5.
    1. Michna E, Ross EL, Hynes WL, Nedeljkovic SS, Soumekh S, Janfaza D, Palombi D, Jamison RN. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage. 2004;28:250–258. doi: 10.1016/j.jpainsymman.2004.04.007.
    1. Chelminski PR, Ives TJ, Felix KM, Prakken SD, Miller TM, Perhac JS, Malone RM, Bryant ME, DeWalt DA, Pignone MP. A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Serv Res. 2005;5:3. doi: 10.1186/1472-6963-5-3.
    1. Fishman SM, Kreis PG. The opioid contract. Clin J Pain. 2002;18:S70–75. doi: 10.1097/00002508-200207001-00008.
    1. Berndt S, Maier C, Schutz HW. Polymedication and medication compliance in patients with chronic non-malignant pain. Pain. 1993;52:331–339. doi: 10.1016/0304-3959(93)90167-N.
    1. Hammett-Stabler CA, Pesce AJ, Cannon DJ. Urine drug screening in the medical setting. Clin Chim Acta. 2002;315:125–135. doi: 10.1016/S0009-8981(01)00714-8.
    1. Cleeland CS. Issues in Pain Measurement. New York, Raven Press; 1989. Measurement of Pain by Subjective Report, in: Anonymous; pp. 391–403.
    1. Cleeland CS. Proceedings of the Second International Congress on Cancer Pain. New York, Raven Press; 1990. Assessment of Pain in Cancer: Measurement Issues, in Anonymous; pp. 47–56.
    1. Chibnall JT, Tait RC. The Pain Disability Index: factor structure and normative data. Arch Phys Med Rehabil. 1994;75:1082–1086. doi: 10.1016/0003-9993(94)90082-5.
    1. Tait RC, Pollard CA, Margolis RB, Duckro PN, Krause SJ. The Pain Disability Index: psychometric and validity data. Arch Phys Med Rehabil. 1987;68:438–41.
    1. Karjalainen K, Malmivaara A, van Tulder M, Roine R, Jauhiainen M, Hurri H, Koes B. Multidisciplinary biopsychosocial rehabilitation for neck and shoulder pain among working age adults. Cochrane Database Syst Rev. 2003:CD002194.
    1. Radloff L. A self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–392.
    1. Davis TC, Long SW, Jackson RH, Mayeaux EJ, George RB, Murphy PW, Crouch MA. Rapid estimate of adult literacy in medicine: a shortened screening instrument. Fam Med. 1993;25:391–395.
    1. Public Access Information System North Carolina Department of Correction. Offender Search. 2002.
    1. Elliott AM, Smith BH, Penny KI, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. Lancet. 1999;354:1248–252. doi: 10.1016/S0140-6736(99)03057-3.
    1. Clark JD. Chronic pain prevalence and analgesic prescribing in a general medical population. J Pain Symptom Manage. 2002;23:131–137. doi: 10.1016/S0885-3924(01)00396-7.
    1. Chabal C, Erjavec MK, Jacobson L, Mariano A, Chaney E. Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors. Clin J Pain. 1997;13:150–155. doi: 10.1097/00002508-199706000-00009.
    1. Webb L, Oyefeso A, Schifano F, Cheeta S, Pollard M, Ghodse AH. Cause and manner of death in drug-related fatality: an analysis of drug-related deaths recorded by coroners in England and Wales in 2000. Drug Alcohol Depend. 2003;72:67–74. doi: 10.1016/S0376-8716(03)00191-1.
    1. Maier C, Hildebrandt J, Klinger R, Henrich-Eberl C, Lindena G. Morphine responsiveness, efficacy and tolerability in patients with chronic non-tumor associated pain – results of a double-blind placebo- controlled trial (MONTAS) Pain. 2002;97:223–233. doi: 10.1016/S0304-3959(02)00020-9.
    1. Portenoy RK, Sciberras A, Eliot L, Loewen G, Butler J, Devane J. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J Pain Symptom Manage. 2002;23:292–300. doi: 10.1016/S0885-3924(02)00382-2.
    1. Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomised trial of oral morphine for chronic non-cancer pain. Lancet. 1996;347:143–147. doi: 10.1016/S0140-6736(96)90339-6.
    1. Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med. 1980;302:123.
    1. Grant BF. Prevalence and correlates of drug use and DSM-IV drug dependence in the United States: results of the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse. 1996;8:195–210. doi: 10.1016/S0899-3289(96)90249-7.
    1. Fishbain DA. Report on the prevalence of drug/alcohol abuse and dependence in chronic pain patients (CPPs) Subst Use Misuse. 1996;31:945–946.
    1. Reid MC, Engles-Horton LL, Weber MB, Kerns RD, Rogers EL, O'Connor PG. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med. 2002;17:173–179. doi: 10.1046/j.1525-1497.2002.10435.x.
    1. Hoffmann NG, Olofsson O, Salen B, Wickstrom L. Prevalence of abuse and dependency in chronic pain patients. Int J Addict. 1995;30:919–927.
    1. Sajan A, Corneil T, Grzybowski S. The street value of prescription drugs. CMAJ. 1998;159:139–142.
    1. Lynskey MT, Heath AC, Bucholz KK, Slutske WS, Madden PA, Nelson EC, Statham DJ, Martin NG. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA. 2003;289:427–433. doi: 10.1001/jama.289.4.427.
    1. Adams LL, Gatchel RJ, Robinson RC, Polatin P, Gajraj N, Deschner M, Noe C. Development of a self-report screening instrument for assessing potential opioid medication misuse in chronic pain patients. J Pain Symptom Manage. 2004;27:440–459. doi: 10.1016/j.jpainsymman.2003.10.009.
    1. Skouen JS, Grasdal AL, Haldorsen EM, Ursin H. Relative cost-effectiveness of extensive and light multidisciplinary treatment programs versus treatment as usual for patients with chronic low back pain on long-term sick leave: randomized controlled study. Spine. 2002;27:901–910. doi: 10.1097/00007632-200205010-00002.
    1. Grabois M. Management of chronic low back pain. Am J Phys Med Rehabil. 2005;84:S29–41.
    1. United States Department of Justice, Drug Enforcement Administration Dispensing of controlled substances for the treatment of pain. Federal Register. 2004;69:67170.
    1. United States Department of Justice, Drug Enforcement Administration Clarification of existing requirements under the Controlled Substances Act for prescribing Schedule II controlled substances. Federal Register. 2005;70:50408–9.
    1. Ziegler SJ, Lovrich NP., Jr Pain relief, prescription drugs, and prosecution: a four-state survey of chief prosecutors. J Law Med Ethics. 2003;31:75–100.
    1. Fleming DA. Relieving pain: what are today's ethical and legal risks? Mo Med. 2002;99:560–565.
    1. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144:127–134.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir